Amerikanische Gesellschaft für Hirudotherapie

Engineering ultrapotent trivalent anticoagulants through hybridisation of salivary peptides from multiple haematophagous organisms

Basic science / drug design published in Chem Sci (2025)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportArzneimittelentwicklungSpeichel-PharmakologieMaxwell JWC et al. · Chemical science, 2025

Abstract

Haematophagous organisms are a rich source of salivary anticoagulant polypeptides that exert their activity by blocking the catalytic site and one of two positively charged exosites on the host protease thrombin. Here, we describe a molecular engineering approach to hybridise post-translationally sulfated polypeptides from different blood-feeding organisms to enhance anticoagulant activity. This led to the discovery of a triply sulfated hybrid anticoagulant, XChimera, possessing fragments from flea, leech, and fly salivary polypeptides that exhibits femtomolar inhibitory activity against thrombin. The crystallographic structure of a complex of XChimera with thrombin shows that it displays a trivalent binding mode in which it simultaneously blocks three functional sites of the protease, the active site and exosites I and II. This trivalent chimera exhibited ultrapotent anticoagulant activity in a suite of in vitro clotting assays and was also shown to possess potent in vivo antithrombotic activity in a murine model of thrombosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Zusammenfassung

Engineering of XChimera, a triply-sulfated hybrid anticoagulant combining flea, leech, and fly salivary peptide fragments. Achieves femtomolar Ki against thrombin via trivalent binding (active site + exosites I & II). Crystal structure resolved; in vivo efficacy in murine thrombosis model.

Warum dies für die Hirudotherapie relevant ist

This study engineered a hybrid anticoagulant (XChimera) by combining sulfated salivary polypeptide fragments from flea, leech, and fly to achieve trivalent blockade of thrombin's active site and both exosites, yielding femtomolar inhibition. XChimera demonstrated potent anticoagulant activity in vitro and antithrombotic efficacy in a murine thrombosis model. For ASH's domain, this work highlights how leech-derived peptides can serve as modular building blocks in rational drug design of next-generation anticoagulants. However, the study is preclinical (in vitro and mouse model), and the leech component is only one of three hybridised fragments; the chimera is not a native leech secretome product and no clinical data are presented.

Zitation

Engineering ultrapotent trivalent anticoagulants through hybridisation of salivary peptides from multiple haematophagous organisms.

Maxwell JWC et al. · Chemical science, 2025

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.